Business & Finance
A generational flight from tech to defensive stocks is underway. How we’re capitalizing
Key Points
Investors can't get enough of boring stocks. According to Morgan Stanley's derivatives group, the fourth quarter so far has seen the biggest rotation into defensive names in 25 years. Since Oct. 1, more than six weeks in, the consumer staples, healthcare, and utilities sectors are up an average of 13% versus a 13% decline in the Nasdaq 100 , which is more heavily weighted toward tech than even the Nasdaq Composite .
Investors can't get enough of boring stocks. According to Morgan Stanley's derivatives group, the fourth quarter so far has seen the biggest rotation into defensive names in 25 years. Since Oct. 1, more than six weeks in, the consumer staples, healthcare, and utilities sectors are up an average of 13% versus a 13% decline in the Nasdaq 100 , which is more heavily weighted toward tech than even the Nasdaq Composite . That 26% performance gap is the largest since September and October 2001 — about 1.5 years after the dotcom bubble burst and roughly a year before the bottom. After chasing tech stocks for most of the four-year-old AI boom, investors have recently sought to reduce their tech exposure and seek out stocks in companies that offer more stability and less volatility. There have been a variety of reasons for the switch — from concerns about debt-fueled AI expansion to the Democratic wave in the midterms to, more recently, the fallout from the Jensen Huang affair scandal at Nvidia . Jim Cramer recognized this trend early, putting the Club portfolio on the leading edge of this rotation and stressing the benefits of diversification. We lightened our load and took profits in stocks tied to the data center buildout, such as exits of Corning in September and Broadcom in October, while initiating and bulking up our defensive positions in consumer staples and healthcare. Here's a closer look at how we're positioned and why we continue to like six stocks spanning these two sectors that went from boring to booming. Consumer staples Kimberly-Clark — The Huggies diaper and Kleenex tissue maker offers exposure to everyday essentials that consumers need regardless of the economic backdrop. Earlier this month, Kimberly-Clark completed its acquisition of Kenvue, which brought consumer health brands, including Tylenol and Band-Aid, under its umbrella. We started a position in Kimberly-Clark in early September, with an eye toward Kenvue being a catalyst in the quarters and years to come. Though our ownership got off to a rocky start, we have added to KMB four times since our initiation to get bigger in a stock Jim has said is one of his favorites right now. By leaning into weakness, we were able to lower our cost basis. Our more recent buy was last Friday, saying in our trade alert that the market is under-appreciating Kimberly-Clark's ability to turn around Kenvue. Costco — The warehouse retailer's stock has gotten its mojo back and demonstrated why it's been such a good one to own for the long term. Jim has frequently touted Costco's competitive pricing and membership-based business model. Plus, last Wednesday's announcement of a $30-per-share special dividend , alongside a new $4 billion share repurchase authorization, underscores the strength of its balance sheet and its commitment to returning capital to shareholders. Since then, the stock has been on a five-session winning streak. A positive finish Tuesday would mean another record-high close. In a Tuesday note, Mizuho raised its price target to $1,150 from $1,100 per share, citing strong October sales and predicting more of the same in November. "Consumer anxiety following the Microsoft Outlook outage, the ground stoppage for all U.S. airline flights, and apocalyptic concerns flaring up across social media have all contributed to increased emergency prep sales at Costco," analysts wrote. Costco is set to report November sales on Dec. 2 and its fiscal 2027 first quarter earnings on Dec. 10. Constellation Brands — While Costco has been a longtime holding of the Club, we recently brought Constellation Brands back into the portfolio, initiating a position earlier this month. Jim said Tuesday that members who don't own shares of the Corona and Modelo brewer, or want to improve their cost basis, should buy on further declines. Jim has said he sought out Constellation as a less cyclical company that also returns capital to shareholders. Alongside Kimberly-Clark, we bought more Constellation shares last Friday. In a "Mad Money" interview back in August, new CEO Nicholas Fink acknowledged that the beer industry has faced pressure as its largely Hispanic consumer base grapples with both inflation and concerns over immigration law enforcement. Things have changed after the election, with the hope that Democratic control of Capitol Hill and more key governorships would help ease worries about deportations. "It's just so positive," Jim said during Monday's Morning Meeting . He added that Constellation's beer is selling better. Healthcare Johnson & Johnson — If there's one stock that perfectly illustrates the market's appetite for defensive stocks, Jim said it is J & J. This week, he called it a " metaphor for what's working." Shares of the pharma and medtech giant briefly touched an all-time intraday high above $290 on Monday after announcing a deal to acquire clinical-stage Ollin Biosciences for approximately $3.3 billion. The deal expands J & J's pipeline of treatments for serious eye diseases. Jim is a fan of J & J's robust drug portfolio and touted Ollin as another reason investors want to own names with tangible growth opportunities outside of AI. Despite an eventual lower close Monday and additional weakness Tuesday, the stock is still up more than 17.5% since we initiated our position back in April. Cardinal Health — This healthcare distributor stock has been a rocket ship lately. During our Annual Meeting earlier this month, Jim reiterated that starting a position in Cardinal Health back in March was a bit early. However, he is pleased that the stock was able to shake its spring swoon — during which we wisely bought more shares — and climb to record highs. Cardinal benefits from its essential role in the healthcare supply chain, with opportunities to improve profitability. Following a great beat-and-raise quarter on Nov. 5, we raised our price target to $300 from $265. We did trim our position once on earnings day and again on Nov. 10 . We locked in profits as a matter of discipline due to the parabolic move higher in the stock. In new notes, Wells Fargo and Barclays raised their price targets to $321 and $320, respectively. The analysts recognize the same potential for further upside as we do. Eli Lilly — Demand for Eli Lilly's blockbuster GLP-1 diabetes and obesity drugs, including injectables Zepbound and Mounjaro, remains central to our investment thesis. The company reported a strong quarter late last month, featuring continued growth in its new Foundayo pill. Last week, the company scored a big win when it became the first drugmaker to win the regulatory green light from China for Foundayo. However, like Cardinal Health, Lilly shares have also been pretty much unstoppable since mid-September. On Nov. 5, we trimmed the position just under Friday's record high price. (Jim Cramer's Charitable Trust is long LLY, JNJ, CAH, STZ, KMB, and COST. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.